MedPath

NALBUPHINE HCI

NALBUPHINE HCI INJ. 10mg/mL 10mL VIAL

Approved
Approval ID

96139914-0708-7b58-e053-2995a90a7308

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Feb 22, 2020

Manufacturers
FDA

HF Acquisition Co LLC, DBA HealthFirst

DUNS: 045657305

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

NALBUPHINE HCI

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code51662-1420
Application NumberANDA070915
Product Classification
M
Marketing Category
C73584
G
Generic Name
NALBUPHINE HCI
Product Specifications
Route of AdministrationINTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS
Effective DateFebruary 22, 2020
FDA Product Classification

INGREDIENTS (9)

HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT
METHYLPARABENInactive
Quantity: 1.8 mg in 1 mL
Code: A2I8C7HI9T
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
NALBUPHINE HYDROCHLORIDEActive
Quantity: 10 mg in 1 mL
Code: ZU4275277R
Classification: ACTIB
TRISODIUM CITRATE DIHYDRATEInactive
Quantity: 0.47 mg in 1 mL
Code: B22547B95K
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
ANHYDROUS CITRIC ACIDInactive
Quantity: 0.63 mg in 1 mL
Code: XF417D3PSL
Classification: IACT
PROPYLPARABENInactive
Quantity: 0.2 mg in 1 mL
Code: Z8IX2SC1OH
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

NALBUPHINE HCI - FDA Drug Approval Details